2,2-Dimethyl-1-pyrrolidin-1-ylbutan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2,2-Dimethyl-1-pyrrolidin-1-ylbutan-1-one
• 化学式: C₁₀H₁₉NO
• 分子量: 169.267
• InChiKey: WYSYSJDOYXAESQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  碘苯二乙酸 、 2,2-Dimethyl-1-pyrrolidin-1-ylbutan-1-one 在 palladium diacetate 、 乙酸酐 作用下， 反应 20.0h， 以78%的产率得到2-methyl-2-(pyrrolidine-1-carbonyl)butyl acetate
  参考文献：
  名称：

  Pd(II)-催化的叔酰胺中C(sp 2 )-H和C(sp 3 )-H键的化学选择性乙酰氧基化

  摘要：

  据报道，在相对温和的反应条件下，钯催化的化学选择性 C(sp 2 )–H 和 C(sp 3 )–H 乙酰氧基化合成有用的叔酰胺。该协议通过弱配位的导向基团 (C=O) 进行，并且需要低催化剂 (1.0 mol%) 负载。多种功能，例如 C(sp 2 )–Cl、C(sp 3 )–Cl、-CF 3、-COOEt 和-NO 2包括吗啉基、哌嗪基和吡咯烷基杂环在内的基团在反应条件下是相容的。该协议的进一步功能化通过水解为醇、醇酸以及还原为叔胺来证明。初步的动力学同位素效应研究支持限速 C-H 键活化过程。

  DOI：

  10.1021/acs.joc.1c00629
• 作为产物：
  描述：

  2,2-二甲基-3-丁烯酸 在 palladium on activated charcoal 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 2,2-Dimethyl-1-pyrrolidin-1-ylbutan-1-one
  参考文献：
  名称：

  Cross-Coupling of sp³ C−H Bonds and Alkenes:  Catalytic Cyclization of Alkene−Amide Substrates

  摘要：

  We herein present a new oxidative cyclization of alkene-amide substrates under neutral and catalytic conditions. This overall transformation requires tandem sp3 C-H activation (at the position adjacent to the amide nitrogen) and C-C bond formation. Specifically, pyrrolidine 1 was converted to pyrrolizidinone 3 and indolizidinone 4 in 66% and 17% yield, respectively, in the presence of [Ir(coe)2Cl]2, the carbene ligand IPr (1:1 metal/ligand ratio, 5-10 mol % of Ir), and the hydrogen acceptor (NBE or TBE, 3-10 equiv). The results presented in this study suggest that complex 10 [IPr-Ir(Cl)(substrate)] is the key intermediate in the catalytic cycle. On the mechanistic front, the key advance was the ability to facilitate C-H activation and alkene insertion in tandem, and in preference to beta-hydride elimination, in the context of amide substrates. With respect to complex synthesis, catalytic and neutral conditions of this method unlock new exciting opportunities as illustrated by regioselective cyclization of the proline-derived substrate 16.

  DOI：

  10.1021/ja049111e

文献信息

• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070219206A1

  公开（公告）日：2007-09-20

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和含有这些化合物的制药组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这种FLAP调节剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或病症。
• 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)
  申请人：Foote Michael Kevin

  公开号：US20080045517A1

  公开（公告）日：2008-02-21

  The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

  该发明涉及一组新型噻吩-吡咯化合物，其化学式为(I)：其中：R1、R2、R3、R4和R5如规范中所定义，这些化合物可用作促性腺激素释放激素拮抗剂。该发明还涉及该化合物的制药配方、使用该化合物的治疗方法以及制备该化合物的过程。
• DGAT1 Inhibitor and Preparation Method and Use Thereof
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20160272651A1

  公开（公告）日：2016-09-22

  The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

  本发明揭示了一种新型DGAT1抑制剂，特别是公式（I）或其药学上可接受的盐的化合物，以及其制备和制药组合物，以及它们在制备用于预防和治疗家族性高胆固醇血症（FCS），肥胖症，高脂蛋白血症或高甘油三酯血症的药物中的用途。
• DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF
  申请人：Medshine Discovery Inc.

  公开号：EP3042907A1

  公开（公告）日：2016-07-13

  The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

  本发明公开了一种新型 DGAT1 抑制剂，特别是式 (I) 化合物或其药学上可接受的盐、其制备方法和药物组合物，以及它们在制备预防和治疗家族性高胆固醇血症 (FCS)、肥胖症、高脂蛋白血症或高甘油三酯血症的药物中的用途。